PHARM.ASSY

PHARM.ASSY has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €149,646 and a net result of €25,201. Equity is growing by about 32% per year across the filed financial years. Its solvency ranks better than 69% of 22,513 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).